evipedia.ai
← Back

Epithalamin for Health & Longevity

Evidence Review created on 08/31/2026 using AI4L / Opus 5

Also known as: Epithalamine, Epithalaminum, Epitalamin, Pineal Gland Peptide Preparation, Pineal Polypeptide Extract

Motivation

Epithalamin is a mixture of small proteins drawn from the pineal gland of cattle — the pea-sized gland in the brain that makes melatonin and helps set the body’s daily rhythm. Researchers in what was then Leningrad developed it in the early 1970s as an injectable preparation meant to restore signals that this gland loses with age. It draws attention because pineal output falls steeply after midlife, and because the same laboratory later reported that older people given repeated courses lived longer than untreated comparison groups.

The preparation has been used in clinical practice in Russia and Ukraine for decades and is sold internationally as a longevity injection, yet nearly the entire published record comes from one research network, and no regulator outside the former Soviet Union has assessed it. A synthetic four-part copy of one active fragment is now the form most people encounter, which makes the two easy to confuse.

This review examines what the human and animal record shows: what Epithalamin is made of, how it is thought to work, what has been measured in people, what is known about its safety, and how strong or weak the support behind each claim is.

Benefits - Risks - Protocol - Conclusion

This section collects high-level overviews of Epithalamin and its synthetic derivative from expert commentators and from narrative scientific reviews.

Four items are listed rather than five: no further source clears this section’s bar of discussing the compound, or the tetrapeptide built from it, in substantial depth. Direct site searches of foundmyfitness.com, peterattiamd.com and lifeextension.com returned no results for either Epithalamin or its synthetic derivative. The single chriskresser.com hit is one passing sentence naming the tetrapeptide inside an interview on biohacking generally, and the only on-topic lifespan.io result is a news report on one mouse egg-cell study; neither is a high-level overview, so neither was included rather than padding the list.

Grokipedia

Epitalon

Grokipedia’s only page for this compound family. Written around the synthetic tetrapeptide, it covers Epithalamin directly: the bovine pineal origin, the Russian human trials, and the absence of independent replication.

Examine

No Examine article exists for Epithalamin.

Examine.com covers dietary supplements and does not typically cover prescription medications. Epithalamin is a prescription injectable in the Russian Federation and has no over-the-counter supplement form, which is the likely reason for its absence.

ConsumerLab

No ConsumerLab article exists for Epithalamin.

ConsumerLab tests retail dietary supplements and does not typically cover prescription medications. Epithalamin is a prescription injectable in Russia, not sold as a supplement in the United States, so no product review exists.

Systematic Reviews

No systematic reviews or meta-analyses for Epithalamin were found on PubMed as of 31 August 2026.

The principal trade-off for this compound is a claimed mortality and function benefit set against an unmeasured long-term safety profile in a bovine-derived injectable. Neither side of that trade-off is represented: the literature contains no systematic review or meta-analysis of the efficacy claim, and none of the safety question.

Mechanism of Action

Epithalamin is not one molecule but a complex of low-molecular-weight peptides (amino-acid chains shorter than proteins) extracted from bovine pineal glands, with most fragments under 10 kilodaltons. Among them is the four-amino-acid sequence Ala-Glu-Asp-Gly, later synthesized on its own as Epitalon.

The proposed mechanism is bioregulation of gene expression. Short peptides are held to enter cells and nuclei, bind promoter regions of DNA, and restart transcription that has fallen silent with age — the position set out by the developers in Khavinson, 2002, whose institute also sells peptide preparations. Reported downstream effects include restored night-time melatonin output, induction of telomerase, higher activity of superoxide dismutase (SOD, an enzyme that neutralizes reactive oxygen), and shifts in interleukin-2 messenger RNA that alter immune signaling.

A competing explanation is non-specific. Epithalamin is a foreign protein hydrolysate given by injection; critics hold that the observed changes could reflect a mild immune stimulus and amino-acid delivery rather than sequence-specific gene regulation, and note that no receptor has been identified for it.

Pharmacologically it behaves as a peptide, not a small molecule. Its constituent peptides are broken down by plasma and tissue peptidases within minutes, giving a very short half-life; there is no cytochrome P450 (CYP, the liver enzyme family that clears most oral drugs) metabolism and therefore no CYP-mediated drug interactions. Radiolabeled Ala-Glu-Asp-Gly distributes rapidly into the cells and nuclei of several tissues, and elimination is as free amino acids.

Historical Context & Evolution

Epithalamin originated in 1971 at the Kirov Military Medical Academy in Leningrad, where Vladimir Khavinson and Vyacheslav Morozov were extracting tissue-specific peptide fractions — then called cytomedins — from calf organs. The pineal fraction was developed alongside a thymic fraction, Thymalin, and both were first intended as immune-restoring agents for personnel exposed to radiation and for oncology patients, not as longevity preparations.

Attention shifted toward aging after Anisimov’s group at the Petrov Institute of Oncology reported that the same preparation raised mean lifespan in fruit flies, mice and rats and lowered spontaneous tumor incidence, summarized after two decades of work in Anisimov et al., 1994. Because pineal melatonin output falls sharply with age, the group proposed the pineal gland as a pacemaker of aging and Epithalamin as a way to reset it.

From the mid-1990s the program moved into human trials in Saint Petersburg and Kyiv, and in the 2000s the active tetrapeptide was synthesized as Epitalon, which has largely displaced the extract commercially.

These findings have not been reproduced by groups outside that network, and the human trials were open-label, small, and reported in abbreviated form. That is a limitation of the evidence rather than a refutation of it: the trials were randomized, remain in the literature unretracted, and no independent group has attempted the mortality endpoints and failed. What changed over time was the evidentiary standard the field applies, not the arrival of contradicting data.

Expected Benefits

High 🟩 🟩 🟩

Reduced All-Cause and Cardiovascular Mortality in Older Adults

Two randomized trials in adults over 60 report lower death rates after repeated injection courses. In Korkushko et al., 2006, twelve years of follow-up in coronary patients with accelerated cardiovascular aging showed fewer deaths overall and half the cardiovascular deaths. In a separate cohort of 266 older adults, Khavinson & Morozov, 2003 report a similar reduction. Both trials come from the same collaborating institutes, which develop and sell peptide preparations; neither was blinded, and no outside group has repeated them.

Magnitude: Over twelve years, all-cause mortality was 28% lower and cardiovascular mortality roughly two-fold lower than control; in the 266-person cohort, mortality fell 1.6–1.8-fold with Epithalamin alone.

Fewer Acute Respiratory Infections

Two randomized trials report fewer respiratory illness episodes. In the 266-person cohort, participants receiving Epithalamin had markedly fewer episodes than controls, alongside reduced clinical manifestations of coronary disease, high blood pressure and osteoarthrosis (wear-and-tear joint degeneration) (Khavinson & Morozov, 2003); the twelve-year coronary trial reports the same endpoint halved (Korkushko et al., 2006). Counts came from unblinded routine records in both, so biased counting cannot be excluded.

Magnitude: Acute respiratory disease incidence fell 2.0–2.4-fold versus control over 6–8 years in the 266-person cohort, and roughly two-fold over twelve years in the coronary trial.

Medium 🟩 🟩

Improved Exercise Tolerance and Physical Work Capacity

A randomized comparison in 79 older coronary patients — 39 given six injection courses over three years, 40 given standard therapy alone — found treated participants held their exercise capacity while controls declined, reported at fifteen years in Korkushko et al., 2011. Functional age indices and cardiovascular aging scores moved in the treated group’s favor as well. The endpoint is a genuine measure of physical function, but it was assessed unblinded in one cohort.

Magnitude: Direction only: physical work capacity was maintained rather than lost, in coronary patients over 60 receiving two courses a year for three years; the published report gives no numerical effect size for this endpoint.

Lower 24-Hour Blood Pressure and Improved Blood Lipids

A randomized study in middle-aged and older women with coronary disease and high blood pressure found that Epithalamin lowered the 24-hour blood-pressure profile and improved lipid measures (Merkur’eva & Ryzhak, 2008). The longer Kyiv trial separately reported normalized carbohydrate and lipid metabolism (Korkushko et al., 2011). Blood pressure is a surrogate validated against real cardiovascular events, which places this above the biomarker items below; the trial is small, single-center, and available in English only as an abstract.

Magnitude: Direction only: mean 24-hour blood pressure and artery-clogging lipid fractions fell in women already receiving standard cardiac therapy; the English-language report states direction without publishing millimeters of mercury or lipid concentrations.

Low 🟩

Normalization of the Nocturnal Melatonin Rhythm

A randomized course in healthy older adults raised night-time melatonin in those whose pineal output was already low, while those with normal output tended to fall (Korkushko et al., 2004). The effect is baseline-dependent, indirect, and measured in one small cohort.

Magnitude: Direction depends on starting point: night-time plasma melatonin rose in participants with low baseline output and drifted downward in those with normal output; the report publishes no concentration figures.

Rebalancing of Pituitary Reproductive Hormones

In 49 men and women, injection moved luteinizing hormone and follicle-stimulating hormone (the two pituitary signals that drive the gonads) and prolactin toward mid-range when they began abnormal, and left normal values unchanged (Slepushkin et al., 1983). Uncontrolled, unblinded, never repeated.

Magnitude: Direction only, and baseline-dependent: below-range concentrations rose and above-range ones fell, with no change at normal baseline; the report gives no hormone concentrations or effect sizes.

Improved Optic Nerve Blood Flow in Unstable Glaucoma

In 28 patients (42 eyes) with unstable glaucoma despite normalized eye pressure, Epithalamin solution widened arterioles of the conjunctiva and optic disc and reduced red-cell clumping (Egorov et al., 2003). Vascular imaging only, not vision or visual-field outcomes; comparative but not randomized.

Magnitude: Direction only: arteriole diameter increased and congestive angiopathy (blood-vessel congestion in the eye) decreased in treated eyes; the report gives no vessel-diameter values or visual-field change.

Improved Retinal Function in Degenerative Eye Disease

Bioregulator courses including Epithalamin improved visual acuity, fundus appearance and retinal function in 104 patients with diabetic retinopathy (Trofimova & Khavinson, 2001), and the tetrapeptide gave a positive clinical effect in degenerative retinal lesions (Khavinson et al., 2002). Combination therapy, unblinded, originating group only.

Magnitude: A positive clinical effect was reported in 90% of treated cases in both reports; neither publishes an acuity change, a control-group rate, or a between-group difference.

Speculative 🟨

Telomere Lengthening and Extended Cell Division Capacity

Human fetal lung fibroblasts treated with the tetrapeptide gained ten extra divisions with re-lengthened telomeres (Khavinson et al., 2004); an independent laboratory reproduced dose-dependent lengthening (Al-Dulaimi et al., 2025). Culture only, no human data.

Enhanced Antioxidant Defenses

Epithalamin raised total antioxidant activity and superoxide dismutase and cut lipid peroxidation products in rodents and in blood cells from patients (Anisimov et al., 2001). These are unvalidated laboratory markers, not outcomes.

Lifespan Extension and Reduced Tumor Incidence in Animals

Mean lifespan rose 11–31% in fruit flies, mice and rats, with lower spontaneous tumor rates (Anisimov et al., 1998). Animal work only; no human lifespan trial has been run.

Benefit-Modifying Factors

  • Baseline melatonin output: The one trial that measured it found benefit confined to participants whose night-time pineal output was already low; those with a preserved rhythm saw no gain and a downward drift, making baseline measurement the single strongest predictor of response.

  • Age: Every human trial enrolled participants over 60, most with accelerated cardiovascular aging. Nothing in the record speaks to people in their forties or fifties, where the age-related decline the preparation targets has barely begun.

  • Sex: The blood-pressure and lipid trial enrolled women only; the mortality trials were mixed but did not report results by sex. Baseline pineal decline and hormone responses differ between sexes, so transfer of the female cardiovascular findings to men is unsupported.

  • Pre-existing conditions: Benefits were shown in coronary disease with accelerated cardiovascular aging, not in healthy adults. The absolute gain from any mortality-reducing intervention scales with baseline risk, so a metabolically healthy user should expect substantially less.

  • Genetic polymorphisms: Variants in AANAT and ASMT (the enzymes that build melatonin) and in MTNR1B (a melatonin receptor gene) plausibly set baseline output and response, and TERT (the gene for the telomere-rebuilding enzyme) variants may set telomere response. None has been tested here.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been documented for Epithalamin in more than one controlled human trial, because the published trials report tolerability only as a summary remark and none contains a graded adverse-event table.

Medium 🟥 🟥

No risk reaches Medium either: no single controlled trial reports a clinical adverse endpoint or a validated clinical surrogate moving in a harmful direction; the human safety record consists only of uncontrolled observations and mechanistic concerns.

Low 🟥

Melatonin Suppression in People with an Intact Pineal Rhythm

The trial that raised night-time melatonin in low-output participants saw it drift downward in those whose rhythm was already normal (Korkushko et al., 2004). For a middle-aged user with preserved melatonin production, the direction of effect may be the wrong one.

Magnitude: Direction only: night-time plasma melatonin fell in participants with normal baseline pineal output after a treatment course; the report publishes no concentrations, so the size of the fall is unknown.

Unpredictable Shifts in Pituitary and Reproductive Hormones

Injection changed luteinizing hormone, follicle-stimulating hormone and prolactin in 49 people, with direction set by baseline (Slepushkin et al., 1983). Anyone on hormone therapy, or with a hormone-sensitive condition, inherits an unpredictable perturbation of an axis they are trying to control.

Magnitude: Direction only, and baseline-dependent: below-range hormone concentrations rose and above-range ones fell after dosing; the report publishes no hormone concentrations or effect sizes.

Speculative 🟨

Transmissible Spongiform Encephalopathy Exposure from Bovine Tissue

Epithalamin is extracted from cattle brain tissue, the class implicated in bovine spongiform encephalopathy (a fatal prion brain disease). No case has been linked to the preparation, and herd sourcing controls vary by manufacturer.

Telomerase and Alternative Lengthening in Malignant Cells ⚠️ Conflicted

Rodent studies report fewer spontaneous tumors, yet an independent 2025 study switched on alternative telomere lengthening in breast cancer lines (Al-Dulaimi et al., 2025). Net reading: animal protection does not exclude a pro-tumor pathway.

Injection-Site Reactions and Immunogenicity

As a foreign protein mixture given intramuscularly, Epithalamin carries the standard risks of a biologic: local pain, swelling, sterile abscess and, rarely, hypersensitivity. Published trials mention no adverse events; no systematic safety collection exists.

Adulteration and Dose Inaccuracy in Grey-Market Supply

Material sold online as Epithalamin or its tetrapeptide is unregulated research chemical: no official identity test, no sterility or endotoxin release, no manufacturer accountability. Contamination and mislabeled content are the practical exposure.

Risk-Modifying Factors

  • Genetic polymorphisms: Carriers of TERT promoter variants or of cancer-predisposition variants such as BRCA1 and BRCA2 (DNA-repair genes) face a theoretically larger downside from any telomere-lengthening exposure, since the same pathway sustains malignant cells.

  • Baseline biomarker levels: A preserved night-time melatonin rhythm converts the melatonin finding from a benefit into a risk, and abnormal baseline gonadotropins predict the largest hormonal shift. Both are measurable before starting.

  • Sex-based differences: The only trial reporting hormonal endpoints included both sexes but did not separate them. Women approaching or past menopause have gonadotropin concentrations far outside young-adult range, which is precisely where the bidirectional shift is largest.

  • Pre-existing conditions: Active or recently treated malignancy, autoimmune disease, and known hypersensitivity to bovine proteins each raise the plausible harm from a foreign-protein injectable with telomerase and immune activity.

  • Age: Older users have the lowest baseline melatonin and so the least suppression risk, but also the highest background cancer incidence, where any pro-proliferative pathway matters most. The two effects pull in opposite directions.

Key Interactions & Contraindications

  • Melatonin receptor agonists (prescription sleep drugs acting on melatonin’s own receptors: ramelteon, tasimelteon): Caution. Additive effect on the same signaling axis; consequence is excessive daytime sedation or a shifted sleep phase. Initiation separated by several weeks keeps any rhythm change attributable.

  • Beta-blockers (drugs that slow the heart and lower blood pressure: propranolol, atenolol, metoprolol): Monitor. These suppress night-time melatonin synthesis and can blunt the preparation’s main measured effect; consequence is apparent non-response. No dose change is indicated, but melatonin testing is interpreted accordingly.

  • Sedative-hypnotics (prescription drugs that induce sleep: zolpidem, eszopiclone, temazepam): Caution. Additive sedation if the melatonin rhythm shifts; consequence is next-morning impairment. Reassessment of the sleep-drug dose falls after the first injection course rather than during it.

  • Over-the-counter melatonin and sedating antihistamines (allergy drugs that also cause drowsiness: diphenhydramine, doxylamine): Caution. Directly additive with the intended pineal effect; consequence is over-sedation and further rhythm displacement. Supplemental melatonin is held during and for two weeks after a course.

  • Over-the-counter analgesics (painkillers that also reduce inflammation: aspirin, ibuprofen, naproxen): Monitor. Regular evening use suppresses nocturnal melatonin secretion and can mask response; consequence is a misleading biomarker result rather than clinical harm.

  • Supplements with additive effects (5-HTP or 5-hydroxytryptophan, the serotonin and melatonin precursor; valerian, magnesium glycinate, tart cherry extract): Caution. All shift sleep onset or melatonin availability in the same direction; consequence is excessive sedation and confounded assessment of response.

  • Telomerase-activating supplements (cycloastragenol, astragalus-derived TA-65): Caution. Additive telomerase induction; consequence is compounding an already speculative proliferative signal with no offsetting evidence of benefit.

  • Immunosuppressants (drugs that damp down the immune system: tacrolimus, ciclosporin, mycophenolate): Caution. Epithalamin was originally developed as an immune stimulant; consequence is a theoretical opposition to intended immunosuppression, relevant after transplant or in controlled autoimmune disease.

  • Other Khavinson-type peptide preparations (Thymalin, Cortexin, Vilon): Monitor. These are routinely co-administered, and the largest reported mortality effect came from combining Epithalamin with Thymalin; consequence is that neither agent’s contribution or adverse effect can be attributed.

  • Bright-light therapy and scheduled evening light restriction: Monitor. Both act on the same circadian pathway; consequence is confounded interpretation. A light schedule fixed before a course leaves any change attributable to the injection.

Populations who should avoid Epithalamin:

  • Active malignancy, or remission of less than 5 years, given the unresolved telomerase and alternative-lengthening signal
  • Pregnancy and lactation — no reproductive toxicology of any kind exists
  • Known hypersensitivity to bovine proteins or to any other animal tissue extract
  • Solid-organ transplant recipients on maintenance immunosuppression
  • Active, uncontrolled autoimmune disease, such as systemic lupus erythematosus with current flare
  • Children and adolescents under 18, in whom the pineal axis is at peak output

Risk Mitigation Strategies

  • Baseline pineal testing before the first dose: Night-time melatonin or its urinary breakdown product is measured between 02:00 and 04:00; a normal result means the suppression risk described above applies and argues against proceeding.

  • Cancer screening current to guideline schedule: Age-appropriate screening completed within 12 months before starting mitigates the telomerase and alternative-lengthening concern by ensuring no occult malignancy is present at exposure.

  • Single-agent, single-variable courses: Epithalamin taken alone rather than combined with Thymalin or other bioregulators allows any adverse effect to be attributed and stopped, rather than being lost across three simultaneous exposures.

  • Documented sourcing to mitigate prion and contamination exposure: Country-of-origin herd documentation, a certificate of analysis, and sterility and endotoxin release testing for each lot address both the bovine tissue risk and grey-market adulteration.

  • Hormone panel before and after each course: Luteinizing hormone, follicle-stimulating hormone and prolactin measured before and 4 weeks after a course detect the unpredictable pituitary shift rather than leaving it assumed absent.

  • Aseptic intramuscular technique with site rotation: Injection sites rotated across the 10-day course, with single-use sterile diluent, mitigate injection-site reactions, sterile abscess and infection from a repeatedly injected protein preparation.

Therapeutic Protocol

  • Standard course used in the trials: 10 mg lyophilized powder reconstituted in sterile saline or 0.5% procaine, injected intramuscularly once daily for 10 consecutive days, as used by the Kyiv Institute of Gerontology group.

  • Course frequency: Two courses per year was the schedule in the 15-year follow-up trial, which delivered six courses across three years. The 266-person cohort used courses over the first 2–3 years only.

  • Competing approach — synthetic tetrapeptide: Practitioners outside Russia more often use synthetic Ala-Glu-Asp-Gly at 5–10 mg daily for 10–20 days, subcutaneously or intranasally, on the argument that a defined single peptide avoids bovine sourcing entirely.

  • Competing approach — oral bioregulator capsules: A capsule form of the pineal peptide complex is marketed for 10–30 day courses, two to three times yearly. No trial has compared oral against injectable, and oral peptide absorption is unresolved.

  • Who popularized each: The injectable course originates with Khavinson and Morozov at the Saint Petersburg Institute of Bioregulation and Gerontology; the Kyiv trials were run by Korkushko’s group at the Institute of Gerontology.

  • Best time of day: Evening dosing is the common practice, on the reasoning that it aligns with the nocturnal melatonin surge the preparation targets. No trial has compared timings, so this rests on mechanism, not data.

  • Half-life and its consequence: Constituent peptides are cleared within minutes, so plasma persistence cannot explain months-long effects. The course design assumes a durable regulatory change, not sustained drug exposure — an assumption never directly tested.

  • Single versus split dosing: Trials used one daily 10 mg injection, never split. Given clearance in minutes, splitting has no pharmacokinetic rationale and would only add injection-site exposure.

  • Genetic polymorphisms and dose: No pharmacogenetic data exist. AANAT, ASMT and MTNR1B variants plausibly shape melatonin response and TERT variants telomere response, but no variant has ever been used to select a dose.

  • Sex-based differences: No trial has reported dose or response by sex. The single female-only trial used the same 10 mg course as the mixed-sex trials, so there is no basis for a sex-adjusted dose.

  • Age-related considerations: All dosing evidence comes from people over 60, including participants in their eighties, who received the same course without dose reduction. Nothing supports extrapolating the schedule below age 60.

  • Baseline biomarkers and response: Low night-time melatonin is the only measured predictor of a positive response. Those with normal baseline output showed the opposite direction and have no evidence-based reason to dose.

  • Pre-existing conditions and response: Trial participants had coronary disease with accelerated cardiovascular aging; the mortality and function results are anchored in that population and do not transfer to healthy adults at low baseline risk.

Discontinuation & Cycling

  • Course-based, not lifelong: The preparation was never given continuously. Every trial used intermittent 10-day courses with months between them, so discontinuation after a course is the design, not a deviation from it.

  • No withdrawal effects reported: No trial describes rebound, withdrawal or deterioration after courses stopped. In the 266-person cohort, dosing ended after 2–3 years while benefits were reported to persist through year 6–8.

  • No tapering required: With clearance in minutes and no receptor occupancy model, there is no pharmacological basis for tapering. Courses in the trials ended abruptly at day 10 without any step-down.

  • Cycling is the standard pattern: Two courses per year is the schedule with the longest follow-up. Whether more frequent cycling adds benefit or accumulates immunogenic exposure has never been tested.

  • Stopping rule: Absence of any change in the baseline marker that justified starting — night-time melatonin — after two full courses is the most defensible reason to stop, since no other measurable response predictor exists.

Sourcing and Quality

  • Source material determines the main risk: Bovine pineal glands from herds in countries with documented bovine spongiform encephalopathy controls; country-of-origin and herd-status documentation is the check that matters, since brain tissue is the highest-risk class for prion transmission.

  • Manufactured versus compounded: Pharmaceutical-grade Epithalamin is produced by Russian manufacturers, including Samson-Med and the Geropharm group, under Russian registration. No Western manufacturer produces it, and no compounding pharmacy holds a validated monograph.

  • What to look for on a certificate of analysis: Peptide identity by high-performance liquid chromatography and mass spectrometry, total peptide content, bacterial endotoxin level, sterility, and residual solvent — the minimum set for an injectable protein product.

  • Synthetic alternative and its own quality problem: Synthetic Ala-Glu-Asp-Gly avoids bovine tissue entirely, but is sold almost exclusively as “research chemical” material with no release testing, so one risk is traded for another.

  • Third-party testing is essential and rarely available: No independent testing organization publishes assay results for this compound. Independent laboratory verification of identity and sterility, commissioned per lot, is the only available substitute.

  • Formulation: Supplied as a 10 mg lyophilized powder for reconstitution. Pre-mixed solutions and unrefrigerated shipments both indicate a supply chain that has not maintained peptide stability.

Practical Considerations

  • Time to effect: Melatonin and hormone changes were measured after a single 10-day course. Function and mortality endpoints emerged only across years of repeated courses, so nothing should be expected within weeks.

  • Common pitfall — combining preparations: The largest reported mortality effect came from combining Epithalamin with Thymalin, and that combination is routinely reproduced in practice. Doing so makes both benefit and harm unattributable to either agent.

  • Common pitfall — confusing the two compounds: The bovine extract and the synthetic tetrapeptide have separate literatures. Most human trial data belong to the extract; most recent cell and animal data belong to the tetrapeptide.

  • Common pitfall — dosing without a baseline: The one measured response predictor is low night-time melatonin. Dosing without measuring it discards the only means of distinguishing likely responders from likely non-responders.

  • Regulatory status: Epithalamin holds Russian drug registration and has never been submitted to the FDA or the European Medicines Agency (EMA). The FDA has assessed only the synthetic tetrapeptide, reviewed by its Pharmacy Compounding Advisory Committee on 24 July 2026 for insomnia.

  • Cost and access: Import is required in most jurisdictions, at roughly US$200–600 per 10-day course plus injection supplies. No health system outside Russia reimburses it, and the FDA review governs compounding, not importation.

  • Structural bias in who funds the evidence: The Saint Petersburg Institute of Bioregulation and Gerontology, source of most evidence here, sells peptide bioregulators and so earns revenue from its own conclusions. The FDA, more skeptical, sells nothing either way.

  • Payer incentives against the cheap comparator: Melatonin, the low-cost comparator, is unpatentable with no sponsor; Epithalamin is import-priced with one. No payer funds either, so none has reason to commission the head-to-head trial.

Interaction with Foundational Habits

  • Sleep: Direct and bidirectional. The proposed mechanism runs through pineal melatonin output, so effects on sleep timing are expected — improved sleep consolidation in those with low baseline output, and possible phase disruption in those with a preserved rhythm (Korkushko et al., 2004). Sleep-wake and evening-light timing is held stable before a course.

  • Nutrition: Indirect. No food interaction is documented for an intramuscular peptide, and no nutrient depletion is described. Adequate tryptophan intake supports the melatonin synthesis pathway the preparation is meant to stimulate; a caloric deficit that suppresses that pathway would plausibly blunt any effect. No trial controlled diet.

  • Exercise: Indirect and potentially potentiating. The best-supported human endpoint is preserved exercise capacity (Korkushko et al., 2011), an outcome that structured aerobic training produces far more reliably on its own. No blunting of training adaptation has been reported, and no timing relative to workouts has been studied.

  • Stress management: Indirect. The preparation was reported to shift adrenaline, noradrenaline and cortisol toward mid-range in the glaucoma study (Egorov et al., 2003), suggesting an interaction with stress-axis tone. Chronic stress suppresses nocturnal melatonin, so unmanaged stress plausibly works directly against the intended effect.

Monitoring Protocol & Defining Success

Before a first course, the aim is to establish whether the one measured predictor of response is present and whether any contraindication applies. Baseline testing therefore covers night-time pineal output, the pituitary hormones the preparation is known to move, and the cardiovascular and metabolic measures that carried the trial endpoints. High-sensitivity C-reactive protein (hs-CRP, a general marker of body-wide inflammation) and hemoglobin A1c (HbA1c, average blood sugar over about three months) round out the metabolic picture. Ongoing testing follows a fixed cadence: the melatonin and hormone panel is repeated at 4 weeks after each 10-day course, the metabolic and cardiovascular panel at 3 months, and the full set every 6–12 months for as long as courses continue. Success is defined narrowly and in advance: a rise in night-time melatonin in someone who started low, with no adverse shift in the hormone panel.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Night-time plasma melatonin Peak above 50 pg/mL between 02:00 and 04:00 The single measured predictor of response Drawn at 02:00–04:00 under dim red light; conventional laboratories publish no reference range at all
Urinary 6-sulfatoxymelatonin Above 20 µg per overnight collection Non-invasive alternative to a night blood draw Overnight urine collection; the main breakdown product of melatonin, so it reflects total night-time output
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) Mid-reference for age and sex Detects the bidirectional pituitary shift reported after dosing LH and FSH are the two pituitary signals driving the gonads; fasting morning draw, and cycle day 3 in menstruating women
Prolactin 5–15 ng/mL The third hormone reported to shift after injection Conventional laboratories accept roughly 4–23 ng/mL in men and 4–30 ng/mL in women, well above this target; drawn at least 1 hour after waking, with nipple stimulation and exercise avoided beforehand, since stress alone raises it
High-sensitivity C-reactive protein (hs-CRP) Below 0.5 mg/L Tracks the inflammatory background the peptide is claimed to lower hs-CRP is a general marker of body-wide inflammation; conventional laboratories call anything under 3.0 mg/L normal, which is far too permissive
Hemoglobin A1c (HbA1c) 4.8–5.4% The trials reported normalized carbohydrate metabolism HbA1c reflects average blood sugar over about 3 months; conventional cut-off for concern is 5.7%. Best paired with fasting insulin
Fasting insulin 2–5 µIU/mL More sensitive than glucose to the metabolic claim Requires a 10–12 hour fast; most laboratories report up to 25 µIU/mL as normal, which conceals early insulin resistance
Apolipoprotein B (ApoB) Below 80 mg/dL, or below 60 mg/dL at high cardiovascular risk Tests the lipid claim with the particle count that actually predicts events Conventional laboratories report anything up to about 110–130 mg/dL as normal, far above this target; ApoB counts every artery-clogging particle, unlike a standard cholesterol panel, and non-fasting sampling is acceptable
24-hour ambulatory blood pressure Daytime mean below 125/75 mmHg The one validated clinical surrogate the trials moved The conventional ambulatory threshold for concern is a daytime mean of 135/85 mmHg, meaningfully looser than this target; ambulatory monitoring rather than clinic readings matches the trial endpoint, which was the whole 24-hour profile including night-time dipping
Leukocyte telomere length No established target exists; track change from the individual’s own baseline instead The mechanism most often claimed for this compound Between-laboratory variation exceeds the expected effect, so only same-laboratory serial measurement is interpretable

Qualitative markers worth tracking alongside the laboratory panel:

  • Sleep onset latency and number of night-time awakenings, recorded in a simple diary
  • Subjective sleep quality and whether waking feels restorative
  • Daytime energy and its stability across the afternoon
  • Cognitive clarity and word-finding, tracked as a weekly self-rating
  • Exercise tolerance at a fixed workload, which is the endpoint the trials actually moved
  • Frequency and duration of respiratory infections across a full season

Emerging Research

  • No registered trials anywhere: A ClinicalTrials.gov search on 31 August 2026 for Epithalamin, Epithalamine and the Ala-Glu-Asp-Gly tetrapeptide returned zero records, so no NCT identifier exists for any trial of this compound, ongoing or completed. Every human result in this review comes from investigator-run studies registered nowhere.

  • Independent telomere replication: Al-Dulaimi et al., 2025 is the first non-Khavinson group to quantify telomere lengthening, reporting dose-dependent extension in normal human cells through telomerase — the strongest independent support for the central mechanism so far.

  • The same study weakens the case: That paper also found alternative telomere lengthening switched on specifically in breast cancer lines. If confirmed, it identifies a route by which the compound could sustain malignant cells rather than only normal ones.

  • Retinal and wound-healing applications: Gatta et al., 2025 reported restored wound healing in a high-glucose retinal cell model of diabetic retinopathy, extending the older human retinal work into a defined mechanism and proposing an eye-drop formulation.

  • Reproductive aging: Yue et al., 2022 reported protection of mouse egg cells against post-ovulatory aging, and Ullah et al., 2025 reported improved bovine egg-cell maturation and post-thaw embryo development — an assisted-reproduction direction with no human counterpart yet.

  • Regulatory review as a research driver: The FDA’s Pharmacy Compounding Advisory Committee reviewed the synthetic tetrapeptide on 24 July 2026 for insomnia. Its briefing package is the first Western regulatory assessment of this peptide family and will set the evidentiary bar for any future application.

  • What would change the picture: A blinded randomized trial run outside the originating network, with pre-registered mortality or function endpoints and a graded adverse-event table, would resolve nearly every uncertainty in this review at once. Nothing of that description is currently planned.

Conclusion

Epithalamin is a mixture of small proteins drawn from cattle pineal glands and given as a short course of injections. The case for it rests on a small set of long-running trials in older adults with heart disease, which reported fewer deaths, preserved physical capacity, fewer chest infections and lower blood pressure, together with restored night-time melatonin in people whose own output had fallen. Those are real health outcomes, and some participants were followed for over a decade.

The weight of that evidence is limited by where it comes from. Almost all of it came from one collaborating group of institutes that also develops and sells these preparations, so a financial interest sits directly behind the published claims. The trials were small, compressed in their reporting, and run with everyone knowing who received the preparation, and no independent group has repeated the survival findings. No regulator has assessed the extract, and the one recent independent laboratory result both supports the central mechanism and raises a question about how it behaves in cancer cells.

The harms are thinly measured rather than absent. Night-time melatonin drifted downward in people whose rhythm was already intact, and the reproductive hormones moved in whichever direction the starting level was off. No trial collected side effects systematically, the material is drawn from cattle brain tissue, and most of what is sold is unregulated. Weighed together: a plausible mechanism, unusually long human follow-up, a safety record never properly gathered, and no independent confirmation of any of it.

Top - Benefits - Risks - Protocol